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The statement made by Debra Schotik Chan in 2001 (Chan
2001) regarding the regulations for use of bulk drugs in
animals being unclear was probably true until last year. In
May 2015 FDA issued a draft guidance on compounding
animal drugs from bulk drug substances (Guidance for
Industry (Draft) (#230) 2015). The guidance included
specific FDA mandated conditions for animal drug com-
pounding for each of: 1) state-licensed pharmacies, 2)
licensed veterinarians or 3) outsourcing facilities. Since
many pharmacy professionals and pharmaceutical scien-
tists work at outsourcing facilities, this guidance is certainly
of importance as it is expected to be finalized in 2016.
The compounding of animal drugs from bulk drug
substances results in a new animal drug that must
comply with the FD&C Act’s approval and indexing
requirements (Steinschneider 2012). FDA has long had a
concern regarding the unrestricted compounding of
animal drug products as it raises the same concerns as
other unapproved animal drugs (Steinschneider 2012). If
the compounded drug is for a food-producing animal, it
may pose a risk to the animals or humans if unsafe tis-
sue residues should occur or it may be ineffective in the
animal (Steinschneider 2012). Also for these products,
there is no mandatory reporting to the FDA of adverse
events drug experiences (Steinschneider 2012). Add-
itionally, these products may undermine the incentives
to develop and submit new animal drug applications to
FDA containing data and information to demonstrate
that the product is safe, effective, properly manufactured,
and accurately labeled (Guidance for Industry (Draft)
(#230) 2015).
Although there has been an increase in the number of
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is essential to provide optimal pharmaceutical care to
veterinary patients especially when medications are not
available in the desired dosage form. Lack of commer-
cially available products, drug dose adjustment, high cost
of finished drug products especially those for certain
neoplastic and immune-mediated diseases, ease of ad-
ministration and flavor compounding to make medica-
tion taste better and enhancing compliance are typically
the main drivers for veterinary compounding. Under the
proposed guidance, FDA does not intend to take action
under sections 512(a), 501(a)(5), and 501(a)(2)(B) of the
FD&C Act (FD&C Act Chapter V) if an outsourcing
facility compounds animal drugs from bulk drug sub-
stances in accordance with the defined applicable condi-
tions published in the document (Guidance for Industry
(Draft) (#230) 2015).
Key features of the conditions mandated by guidance
include (Guidance for Industry (Draft) (#230) 2015):
 When finalized the document will be populated
with a list of bulk drug substances (Appendix A of
FDA guidance)
for use by outsourcing facilities
 The veterinarian’s prescription specifies that the drug
is intended to treat the species and condition(s) for
which the substance is listed in Appendix A
 The drug is not intended for use in food-producing
animals and that it is compounded under cGMP
 Providing FDA with biannual reports on
outsourcing activities
 Mandatory reporting to FDA of serious-adverse
events
 Adequate labeling of compounded animal drug
(Guidance for Industry (Draft) (#230) 2015).
Appendix A of FDA guidance containing the list of
bulk drug substance is probably the center piece of thisis distributed under the terms of the Creative Commons Attribution 4.0
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drug substances for the list. FDA established a set of cri-
teria that had to be met for a drug candidate to be added
to the list. Those criteria included no marketed approved
animal drug that can be used as labeled to treat the condi-
tion, there is no marketed approved animal or human
drug that could be used under section 512(a)(4) or (a)(5)
and 21 CFR Part 530 to treat the condition (extralabel
use), the drug cannot be compounded from approved
animal or human drug, immediate treatment with com-
pounded drug is necessary to avoid animal suffering or
death and FDA has not identified a significant safety con-
cern specific to the use of bulk drug substance (Guidance
for Industry (Draft) (#230) 2015). Outsourcing facilities
seeking to compound animal drug should be registered
under section 503B of the FD&C act(Guidance for indus-
try 2014). The compounding facility would need to have a
prescription from a veterinarian for an individually identi-
fied animal patient or an order from veterinarian for veter-
inarian office use (Guidance for Industry (Draft) (#230)
2015).
Overall the draft guidance tightens FDA control of
compounding animal drugs from bulk drug substances.
The new documentation requirements represent added
paper work burden on compounding outsourcing facil-
ities, pharmacies and the veterinarian. For the prescrib-
ing veterinarian, it will require justification based on
clinical evidence in the individually identified animal pa-
tient that the compounded drug effect would be differ-
ent from that of the FDA approved animal or human
drug product. That may not be an easy case to make. It
is true that if the approved drug dose is too large for the
intended animal patient and the dosage form cannot be
divided or diluted into the small dose required then that
would be a good justification for requiring a com-
pounded drug and expecting a clinical difference from a
lower dose (Chan 2001). However, there may be cases
where it is difficult to dose the approved formulation in
a particular animal. That may be the case especially for
cats which are hard to dose in general but also it could
be due to the volume of the dose of medication that
needs to be smaller, or removing the bitter taste by add-
ing an appealing flavor (Davis 1997). The prescribing
veterinarian should provide a statement accompanying
the prescription documenting the clinical difference for
the individually identified animal patient. Methimazole,
a drug commonly used for the treatment of feline hyper-
thyroidism is available as oral coated tablets. The twice-
a-day regimen chronic treatment as might be expected
can be difficult for the owners of uncooperative animals
which has led to the development of transdermal op-
tions for drug administration. Results from several clin-
ical studies have shown that while the transdermal gel is
not as effective as the oral dosage from it is still a viablealternative in the treatment of feline hyperthyroidism
(Lecuyer et al. 2006; Sartor et al. 2004). This represents an
opportunity for compounding pharmacies and outsour-
cing facilities seeking to satisfy an unmet need for veterin-
ary patients. It should also be noted that compounding
facilities that are engaged in compounding sterile prepara-
tions have to comply with USP Chapter <797> to
minimize contamination risks to patients. One new re-
striction in the guidance deals with compounded drug
products for “office use”. Under the draft guidance every
animal prescription to be compounded from bulk drug
substance has to correspond to an individually identified
animal patient. Limitations on the amount of compound-
ing done in advance of receipt of a prescription were spe-
cified. That amount should not exceed the amount of
drug product that the state-licensed pharmacy com-
pounded based on a patient-specific prescriptions and the
history of receipt of such patient-specific prescriptions for
that drug product over any consecutive 14-day period
within the previous 6 months (Guidance for Industry
(Draft) (#230) 2015). Some veterinary state boards already
restrict having compounded drugs from a compounding
pharmacy kept at the veterinarian clinic for “office use”
(State of the State of Drug compounding on Minnesota).
For the compounding pharmacist, documentation is
needed that the compounded drug cannot be made from
the FDA-approved drug(s). For example, if a manufacturer
discontinues a product or a prolong shortage is expected
but the specific animal medication need still exist. Other
cases may include the pharmacist noting a potential physi-
cochemical incompatibility when the approved product is
to be mixed or diluted with other ingredients per the vet-
erinarian prescription. The pharmacy should confirm that
compounded drug is not intended for use in food-
producing animals by checking that the prescription or ac-
companying document contains the statement “This pa-
tient is not a food-producing animal”. The new guidance
will require both the compounding pharmacist and the
prescribing veterinarian to engage in more communica-
tion/coordination which is to the benefit of the animal pa-
tient. It should be noted that many of the conditions set
by FDA are standard practice that most compounding fa-
cilities would be expected to be observing including good
compounding practices, code of ethics (Code of ethics-
International Academy of Compounding) and operating
in accordance with USP/NF Chapters <795> and <797>.
Conclusions
It is the hope that once populated with bulk drug sub-
stances, Appendix A would reflect a comprehensive and
diverse list of bulk drug substances from which com-
pounded products can offer therapies that are currently
not available to animal patients. Personalized medicine
should not be a theme restricted to the human
Karara AAPS Open  (2016) 2:5 Page 3 of 3population. Outsourcing facilities serving the com-
pounding needs for the veterinary patient play an im-
portant role in providing optimal pharmaceutical care in
that special population.
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